Bringing a product through the regulatory process requires knowing when to push back, when to go along, and when to change course. Our attorneys have helped bring many FDA-regulated products through the process: drugs and biological products, medical devices, controlled substances, foods, food additives, food contact substances, over-the-counter drugs, and veterinary drugs and devices.
We assist clients with agency meetings, understanding the data required for marketing authorization of a product, and, when appropriate, appealing agency decisions.
HPM advises clients on premarket issues and approval strategies, including:
- Requirements for Investigational Products (INDs and IDEs)
- Clinical Studies and Clinical Holds
- Marketing Authorizations for all FDA regulated products
- Medical Device Premarket Notifications (510(k)s)
- De Novo Petitions
- Premarket Approval Applications (PMAs)
- New Drug Applications (NDAs)
- Biological License Applications (BLAs)
- New Animal Drug Applications (NADAs)
- Food Additive Petitions (FAPs)
- Color Additive Petitions (CAPs), etc.)
- 513(g) Requests
- Meetings with FDA
- Product Reclassification
- Orphan Products (Orphan Drugs, Humanitarian Devices, Minor Use/Minor Species Drugs)
- Product Approval Strategies
- Preparation for FDA Advisory Committee / Advisory Panel meetings